Acadia Pharmaceuticals
ACAD
212 hedge funds and large institutions have $4.44B invested in Acadia Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 72 reducing their positions, and 24 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
42% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 24
33% more capital invested
Capital invested by funds: $3.34B → $4.44B (+$1.1B)
4% more funds holding
Funds holding: 203 → 212 (+9)
7% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 72
1.9% less ownership
Funds ownership: 98.15% → 96.25% (-1.9%)
38% less call options, than puts
Call options by funds: $44.1M | Put options by funds: $71.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$74.7M |
| 2 |
BlackRock
New York
|
+$26M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$16.9M |
| 4 |
TA
Teachers Advisors
New York
|
+$13.1M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$44.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.1M |
| 3 |
SIG
Senator Investment Group
New York
|
-$18.1M |
| 4 |
Millennium Management
New York
|
-$17.2M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$17.1M |
ACAD Hedge Fund Activity: Q3 2017 in Review
212 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2017, worth a combined $4.44B — up 33% from $3.34B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ACAD positions and 24 closed out — a net gain of 10 holders — while 67 added to existing stakes and 72 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $74.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $44.7M.
- 212 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2017, up from 203 in Q2 2017.
- Funds reported $4.44B of Acadia Pharmaceuticals stock for Q3 2017, up 33% quarter-over-quarter.
- 34 funds opened new Acadia Pharmaceuticals positions in Q3 2017 and 24 closed out, a net change of +10 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2017 was Janus Henderson Group, an estimated $74.7M added.
- The largest Acadia Pharmaceuticals seller in Q3 2017 was T. Rowe Price Associates, an estimated $44.7M sold.
Based on aggregated 13F filings for Q3 2017.